Balancing Trajectory and Velocity: Encouraging Sustainable Growth in Biotech
Summary: In biotech, there’s a big difference between “trajectory” and “velocity.” Getting a drug to market quickly, after all, doesn’t always mean that you’re on the path to building a sustainable company. For your biotech to thrive over the long term, it’s critical to continue any forward momentum while ensuring you don’t run out of fuel halfway through your journey.
But how can an emerging biotech balance both sides for the lasting viability of their business? Read further to hear how Andrew Strong, partner at Pillsbury Winthrop Shaw Pittman LLP, feels about it. Andrew has represented private and public company clients in life sciences, technology, energy, and transportation over the past 25 years.